Lake Forest-based Rosetta Genomics Ltd. announced the research collaboration with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab in lung cancer patients.

The study will be led by Jair Bar, M.D., Deputy Director-Institute of Oncology, Sheba Medical Center.

“The development of a new microRNA biomarker signature to predict response to Opdivo in lung cancer patients fits well with our comprehensive lung-specific menu that assists in diagnosis, prognosis, and prediction to therapy for lung cancer patients,” stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

Rosetta Genomics Ltd. is a leading developer and provider of microRNA-based and other molecular diagnostics. For more information, please visit http://rosettagx.com/.